Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

Inclusion Criteria: * Patients with history of mild to moderate Ulcerative Colitis confirmed by endoscopy and pathology. * Total Mayo score 4-9, endoscopic subscore ≥1; patients who have not had endoscopic evaluation within one year of enrollment will have flexible sigmoidoscopy for evaluation. * Age 18 - 64 and deemed otherwise healthy at the discretion of the investigator. * Concurrent therapies with mesalamine (stable x 4 weeks), immunomodulators (stable x 3 months), and biologic agents (stable x 3 months) will be allowed to continue during study. * If patient is on prednisone, the dose must be ≤ 10mg/day at the time of treatment and will be weaned by 2.5mg/week during the study period. Exclusion Criteria: * Severe or refractory UC defined as Mayo score ≥10, endoscopic disease activity score 3 * Untreated enteric infection (positive stool test for any of the following: Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic E. coli or other enteric infection at the discretion of the investigator. * History of colectomy * Disease limited to distal proctitis * Patients taking probiotics within 6 weeks of planned FMT therapy. * Severe immunodeficiency, inherited or acquired (e.g. HIV, chemotherapy or radiation therapy) * Patients with the following laboratory abnormalities: absolute neutrophil count (ANC) \< 1000 / µl, platelets \<50 x 10\^9 /L,, hemoglobin \<6.5 g/dL.. * History of anaphylaxis (severe allergic reaction) to food allergens (e.g. tree nuts, shellfish) * Dysphagia (oropharyngeal, esophageal, functional, neuromuscular) * History of recurrent aspiration episodes * Documented severe gastroparesis * Active intestinal obstruction * Patients with renal insufficiency (GFR \< 50ml/min) * Allergy to the following generally regarded as safe ingredients (GRAS): glycerol, acid resistant HPMC, gellan gum, cocoa butter, titanium dioxide * Adverse event attributable to any previous FMT * Allergy/intolerance to proton pump inhibitor therapy * Allergy/intolerance to vancomycin, metronidazole, or neomycin. * Non-steroidal inflammatory medications (NSAIDs) as long-term treatment, defined as use for at least 4 days a week each month. * Cholestyramine use * Any condition in which the investigator thinks the FMT treatment may pose a health risk (e.g. severely immunocompromised) * Simultaneous participation in another interventional clinical trial * Patients who are pregnant, breast feeding or planning pregnancy during study trial period. * During the trial period until one week after the trial end: Non-use of appropriate contraceptives in females of childbearing potential (e.g. condoms, intrauterine device (IUD), hormonal contraception, or other means considered adequate by the responsible investigator) or in males with a child-fathering potential (condoms, or other means considered adequate by the responsible investigator during treatment) or well-founded doubt about the patient's cooperation * Patients with any other significant medical condition that could confound or interfere with evaluation of safety, tolerability or prevent compliance with the study protocol at the discretion of the investigator * Life expectancy \<6 months